Lataa...
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment
In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS) owing to the approval of a number of new drugs with very distinct mechanisms of action. All approved disease-modifying drugs primarily work directly on the immune system. However, the identification of an ‘o...
Tallennettuna:
| Julkaisussa: | Ther Adv Neurol Disord |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6444778/ https://ncbi.nlm.nih.gov/pubmed/30967901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286419836571 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|